IGF2BP3 and hepatocellular carcinoma: A previous study suggested that m6A reader IGF2BP3 induces sorafenib resistance in HCC by modulating NRF2 expression.[16] However, whether the therapeutic outcomes of targeted drugs in HCC are influenced by glycolysis/gluconeogenesis‐derived serine metabolism and RNA m6A modification remains elusive.